Biologics Market

Biologics Market (Product: Monoclonal Antibodies, Recombinant Proteins, Vaccines, Cell & Gene Therapy, and Others; and Application: Oncology, Autoimmune & Immunological Disorders, Hematological Disorders, Infectious Diseases, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Biologics Market Outlook 2031

  • The global industry was valued at US$ 515.6 Bn in 2022
  • It is projected to grow at a CAGR of 6.9% from 2023 to 2031 and reach more than US$ 855.8 Bn by 2031

Analysts’ Viewpoint

The biologics market is poised for continued growth with several upcoming trends driving innovation. One of the key trends is the surge in demand for personalized medicine, leading to the development of targeted biologic therapies tailored to individual patient profiles.

Advancements in biotechnology, including gene editing and synthetic biology, are opening new avenues for the development of novel biologics with enhanced efficacy and reduced side effects.

The rise of biosimilars, which are highly comparable versions of approved biologics, is expected to fuel market progress by providing more affordable treatment options and fostering competition.

Furthermore, the expansion of biologics into new therapeutic areas such as gene therapy and regenerative medicine is likely to drive biologics market growth.

Market Introduction

Biologics are a class of medicinal products derived from living organisms or containing components of living organisms. Unlike traditional chemical drugs, which are synthesized through chemical processes, biologics are typically large, complex molecules such as proteins, nucleic acids, or antibodies that are produced through biotechnological processes involving living cells.

Applications of biologics span across various fields, including medicine, agriculture, and environmental science. In medicine, biologics have revolutionized the treatment of various diseases, including cancer, autoimmune disorders, infectious diseases, and genetic disorders.

Attribute Detail
Driver Strong Pipeline with Accelerated Approval

Strong Pipeline with Accelerated Approval

A robust pipeline and accelerated approval from regulatory bodies is fueling the biologics market size by hastening the development and commercialization of novel therapies. Major pharmaceutical companies such as Pfizer, are actively advancing numerous biologics across various therapeutic indications within their pipelines.

Regulatory agencies, recognizing the critical need for innovative treatments, have introduced pathways for accelerated approval, enabling promising biologics to reach patients more rapidly while still upholding stringent safety and efficacy standards.

For instance, during the COVID-19 pandemic, governments authorized the manufacturing of biological vaccines. In 2021, the World Health Organization (WHO) granted an emergency use listing (EUL) for COVAXIN, developed by Bharat Biotech, expanding the array of vaccines endorsed by WHO for combating COVID-19.

This streamlined process minimizes development timelines and facilitates swifter market entry for biologic therapies aimed at treating various diseases.

Consequently, pharmaceutical companies are intensifying their research and development efforts, particularly in the realm of cell and gene therapies, to expand their biologics pipelines. Although over 1,500 clinical trials for cell and gene therapies are ongoing, the vast majority remain in early phases, indicating a lengthy path to commercialization for most.

Nonetheless, the presence of accelerated approval pathways fosters collaboration between industry and regulatory bodies, creating a supportive environment for innovation and sustaining the growth trajectory of the biologics market.

Extensive Use of Monoclonal Antibodies in Oncology and Autoimmune Disorders

The biologics market segmentation based on product includes monoclonal antibodies, recombinant proteins, vaccines, cell & gene therapy, and others. The monoclonal antibodies segment is projected to dominate the global market during the forecast period.

Monoclonal antibodies have fewer adverse effects due to their high specificity. Hence, mAbs have become the predominant class of new drugs developed in the last few years.

In the past five years, antibodies have become the best-selling drugs in the pharmaceutical market, and in 2022, out of the top five bestselling prescription drugs worldwide two were mAbs -Keytruda (pembrolizumab), and Humira (adalimumab).

The segment’s dominance is primarily ascribed to surge in adoption of monoclonal antibodies for large unmet medical needs in the fields of oncology and autoimmune disorders.

Recombinant proteins are expected to grow at the fastest pace during the forecast period. Recombinant proteins which are also known as highly potent medicines are safe from off-target side effects, and take a shorter time to develop than other biologics.

Oncology Application Gaining Traction

As per the biologics market analysis, the oncology segment is projected to dominate based on application, during the forecast period. Cancer continues to be one of the leading causes of mortality worldwide. The development of biologics has transformed oncology treatment in recent decades.

A wide range of monoclonal antibodies, therapeutic vaccines, checkpoint inhibitors, and other biologic drugs are now available to treat both solid and blood cancers more effectively. As new targets are discovered, the oncology biologics pipeline is teeming with novel therapies, consequently boosting the global market value.

Some of the top selling oncology biologics include Avastin, Rituxan, Herceptin, Opdivo, and Keytruda. These biologic drugs generated billions in annual sales combined and have greatly improved survival rates for cancer types such as breast, lung, and blood cancers compared to conventional chemotherapy alone.

Given the high prevalence and unmet needs in oncology, biopharma companies prioritize this segment for R&D investment.

High Demand for In-house Manufacturing

The global biologics market trends indicate that the in-house segment is currently dominant, in terms of manufacturing. Large biopharma companies have traditionally favored building internal manufacturing capabilities to maintain high quality standards and confidentiality over their biologic drug development processes.

Developing an in-house manufacturing plant requires huge capital investments but provides long-term control over production.

Smaller biotech companies often lack the resources to establish their own commercial-scale manufacturing facilities from the outset. For early-stage clinical development too, outsourcing production to Contract Development and Manufacturing Organizations (CDMOs) proves more practical and economical.

This has significantly boosted the outsourced segment. For example, many novel CAR-T and gene therapies in development rely entirely on CDMOs for manufacturing scale-up and commercial supply.

Regional Outlook of Global Biologics Industry

Attribute Detail
Leading Region North America

According to the latest biologics market forecast, the pharmaceutical sector in North America has long been a significant player for new biologics.

Anticancer drugs, as well as enhanced immune class drugs, have been at the forefront of North America’s biologic product development, including cutting-edge technologies such as checkpoint inhibitors (e.g. PD1), chimeric antigen receptor (CAR)-T-cell therapies, antibody drug conjugates (ADCs), and monoclonal antibodies (mAbs).

Asia Pacific also has a significant biologics market share. The region is witnessing substantial investments in healthcare infrastructure, research and development, and biotechnology innovation, particularly in countries such as China, India, and South Korea.

These investments are fostering the development and manufacturing of biologic medicines within the region, offering lucrative biologics industry opportunities.

Analysis of Key Players

As per the biologics market report, leading players are focusing on strategies such as new product launches, mergers, partnerships, and collaborations to strengthen their position.

AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Pfizer Inc., and F. Hoffmann-La Roche AG are the prominent biologics market manufacturers.

Key Developments

  • In February 2024, a multiyear partnership has been signed between AbbVie Inc. and Tentarix Biotherapeutics, centered on the identification and advancement of conditionally-active, multi-specific biologic candidates in the fields of immunology and oncology.
  • In September 2023, Novartis announced that it is investing in next-generation bio-therapeutics by establishing a fully integrated, dedicated US$ 300 million scientific environment across existing Novartis locations in Switzerland, Slovenia, and Austria that will increase its capacity and capabilities for early technical development of biologics.
  • In August 2021, Amgen signed a pharmaceutical acquisition agreement with Teneobio to discover and develop new biologics to treat a variety of diseases across Amgen's therapy areas.

Each of these players have been profiled in the global biologics market research report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and latest developments.

Global Biologics Market Snapshot

Attribute Detail
Market Value in 2022 US$ 515.6 Bn
Market Forecast Value in 2031 More than US$ 855.8 Bn
Growth Rate (CAGR) 6.9%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Units US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, and parent industry overview.
Competition Landscape Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Product
    • Monoclonal Antibodies
    • Recombinant Proteins
    • Vaccines
    • Cell & Gene Therapy
    • Others
  • Application
    • Oncology
    • Autoimmune & Immunological Disorders
    • Hematological Disorders
    • Infectious Diseases
    • Others (Cardiovascular Disorders, etc.)
  • Manufacturing
    • Outsourced
    • In-house
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa
Companies Profiled
  • AbbVie
  • Amgen
  • AstraZeneca
  • Bristol-Myers Squibb Company
  • Eli Lilly
  • Gilead Sciences, Inc.
  • GlaxoSmithKline
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • F. Hoffmann-La Roche AG and Others
  • Other Players
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global biologics market in 2022?

It was valued at US$ 515.6 Bn in 2022

How big will the biologics business be by 2031?

It is projected to reach more than US$ 855.8 Bn by the end of 2031

What will be the CAGR of the biologics industry during the forecast period?

The CAGR is anticipated to be 6.9% from 2023 to 2031

Which region will account for major share of the biologics sector during the forecast period?

North America is expected to account for largest share from 2023 to 2031

Who are the prominent biologics players?

AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb Company, Eli Lilly, Gilead Sciences, Inc., GlaxoSmithKline, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., and F. Hoffmann-La Roche AG

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Biologics Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Biologics Market Analysis and Forecasts, 2017–2031

            4.4.1. Market Revenue Projections (US$ Bn)

    5. Key Insights

        5.1. Key Industry Events

        5.2. Porter's Five Forces Analysis

        5.3. Disease Prevalence & Incidence Rate by Region/Globally

        5.4. Regulatory Scenario by Region/Globally

        5.5. Value Chain Analysis

        5.6. COVID 19 Impact Analysis

    6. Global Biologics Market Analysis and Forecasts, By Product

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Product, 2017–2031

            6.3.1. Monoclonal Antibodies

            6.3.2. Recombinant Proteins

            6.3.3. Vaccines

            6.3.4. Cell & Gene Therapy

            6.3.5. Others

        6.4. Market Attractiveness By Product

    7. Global Biologics Market Analysis and Forecasts, By Application

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Application, 2017–2031

            7.3.1. Oncology

            7.3.2. Autoimmune & Immunological Disorders

            7.3.3. Hematological Disorders

            7.3.4. Infectious Diseases

            7.3.5. Others

        7.4. Market Attractiveness By Application

    8. Global Biologics Market Analysis and Forecasts, By Manufacturing

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By Manufacturing, 2017–2031

            8.3.1. Outsourced

            8.3.2. In-house

        8.4. Market Attractiveness By Manufacturing

    9. Global Biologics Market Analysis and Forecasts, By Region

        9.1. Key Findings

        9.2. Market Value Forecast By Region

            9.2.1. North America

            9.2.2. Europe

            9.2.3. Asia Pacific

            9.2.4. Latin America

            9.2.5. Middle East & Africa

        9.3. Market Attractiveness By Country/Region

    10. North America Biologics Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast By Product, 2017–2031

            10.2.1. Monoclonal Antibodies

            10.2.2. Recombinant Proteins

            10.2.3. Vaccines

            10.2.4. Cell & Gene Therapy

            10.2.5. Others

        10.3. Market Value Forecast By Application, 2017–2031

            10.3.1. Oncology

            10.3.2. Autoimmune & Immunological Disorders

            10.3.3. Hematological Disorders

            10.3.4. Infectious Diseases

            10.3.5. Others

        10.4. Market Value Forecast By Manufacturing, 2017–2031

            10.4.1. Outsourced

            10.4.2. In-house

        10.5. Market Value Forecast By Country, 2017–2031

            10.5.1. U.S.

            10.5.2. Canada

        10.6. Market Attractiveness Analysis

            10.6.1. By Product

            10.6.2. By Application

            10.6.3. By Manufacturing

            10.6.4. By Country

    11. Europe Biologics Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Product, 2017–2031

            11.2.1. Monoclonal Antibodies

            11.2.2. Recombinant Proteins

            11.2.3. Vaccines

            11.2.4. Cell & Gene Therapy

            11.2.5. Others

        11.3. Market Value Forecast By Application, 2017–2031

            11.3.1. Oncology

            11.3.2. Autoimmune & Immunological Disorders

            11.3.3. Hematological Disorders

            11.3.4. Infectious Diseases

            11.3.5. Others

        11.4. Market Value Forecast By Manufacturing, 2017–2031

            11.4.1. Outsourced

            11.4.2. In-house

        11.5. Market Value Forecast By Country, 2017–2031

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Italy

            11.5.5. Spain

            11.5.6. Rest of Europe

        11.6. Market Attractiveness Analysis

            11.6.1. By Product

            11.6.2. By Application

            11.6.3. By Manufacturing

            11.6.4. By Country/Sub-region

    12. Asia Pacific Biologics Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Product, 2017–2031

            12.2.1. Monoclonal Antibodies

            12.2.2. Recombinant Proteins

            12.2.3. Vaccines

            12.2.4. Cell & Gene Therapy

            12.2.5. Others

        12.3. Market Value Forecast By Application, 2017–2031

            12.3.1. Oncology

            12.3.2. Autoimmune & Immunological Disorders

            12.3.3. Hematological Disorders

            12.3.4. Infectious Diseases

            12.3.5. Others

        12.4. Market Value Forecast By Manufacturing, 2017–2031

            12.4.1. Outsourced

            12.4.2. In-house

        12.5. Market Value Forecast By Country/Sub-region, 2017–2031

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of APAC

        12.6. Market Attractiveness Analysis

            12.6.1. By Product

            12.6.2. By Application

            12.6.3. By Manufacturing

            12.6.4. By Country/Sub-region

    13. Latin America Biologics Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Product, 2017–2031

            13.2.1. Monoclonal Antibodies

            13.2.2. Recombinant Proteins

            13.2.3. Vaccines

            13.2.4. Cell & Gene Therapy

            13.2.5. Others

        13.3. Market Value Forecast By Application, 2017–2031

            13.3.1. Oncology

            13.3.2. Autoimmune & Immunological Disorders

            13.3.3. Hematological Disorders

            13.3.4. Infectious Diseases

            13.3.5. Others

        13.4. Market Value Forecast By Manufacturing, 2017–2031

            13.4.1. Outsourced

            13.4.2. In-house

        13.5. Market Value Forecast By Country/Sub-region, 2017–2031

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of LATAM

        13.6. Market Attractiveness Analysis

            13.6.1. By Product

            13.6.2. By Application

            13.6.3. By Manufacturing

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Biologics Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Product, 2017–2031

            14.2.1. Monoclonal Antibodies

            14.2.2. Recombinant Proteins

            14.2.3. Vaccines

            14.2.4. Cell & Gene Therapy

            14.2.5. Others

        14.3. Market Value Forecast By Application, 2017–2031

            14.3.1. Oncology

            14.3.2. Autoimmune & Immunological Disorders

            14.3.3. Hematological Disorders

            14.3.4. Infectious Diseases

            14.3.5. Others

        14.4. Market Value Forecast By Manufacturing, 2017–2031

            14.4.1. Outsourced

            14.4.2. In-house

        14.5. Market Value Forecast By Country/Sub-region, 2017–2031

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of MEA

        14.6. Market Attractiveness Analysis

            14.6.1. By Product

            14.6.2. By Application

            14.6.3. By Manufacturing

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Share Analysis By Company (2022)

        15.2. Company Profiles

            15.2.1. AbbVie, Inc.

                15.2.1.1. Company Overview

                15.2.1.2. Financial Overview

                15.2.1.3. Product Portfolio

                15.2.1.4. Business Strategies

                15.2.1.5. Recent Developments

            15.2.2. Amgen

                15.2.2.1. Company Overview

                15.2.2.2. Financial Overview

                15.2.2.3. Product Portfolio

                15.2.2.4. Business Strategies

                15.2.2.5. Recent Developments

            15.2.3. AstraZeneca

                15.2.3.1. Company Overview

                15.2.3.2. Financial Overview

                15.2.3.3. Product Portfolio

                15.2.3.4. Business Strategies

                15.2.3.5. Recent Developments

            15.2.4. Bristol-Myers Squibb Company

                15.2.4.1. Company Overview

                15.2.4.2. Financial Overview

                15.2.4.3. Product Portfolio

                15.2.4.4. Business Strategies

                15.2.4.5. Recent Developments

            15.2.5. Eli Lilly

                15.2.5.1. Company Overview

                15.2.5.2. Financial Overview

                15.2.5.3. Product Portfolio

                15.2.5.4. Business Strategies

                15.2.5.5. Recent Developments

            15.2.6. Gilead Sciences, Inc.

                15.2.6.1. Company Overview

                15.2.6.2. Financial Overview

                15.2.6.3. Product Portfolio

                15.2.6.4. Business Strategies

                15.2.6.5. Recent Developments

            15.2.7. GlaxoSmithKline

                15.2.7.1. Company Overview

                15.2.7.2. Financial Overview

                15.2.7.3. Product Portfolio

                15.2.7.4. Business Strategies

                15.2.7.5. Recent Developments

            15.2.8. Johnson & Johnson Services, Inc.

                15.2.8.1. Company Overview

                15.2.8.2. Financial Overview

                15.2.8.3. Product Portfolio

                15.2.8.4. Business Strategies

                15.2.8.5. Recent Developments

            15.2.9. Merck & Co. Inc.

                15.2.9.1. Company Overview

                15.2.9.2. Financial Overview

                15.2.9.3. Product Portfolio

                15.2.9.4. Business Strategies

                15.2.9.5. Recent Developments

            15.2.10. Novartis AG

                15.2.10.1. Company Overview

                15.2.10.2. Financial Overview

                15.2.10.3. Product Portfolio

                15.2.10.4. Business Strategies

                15.2.10.5. Recent Developments

            15.2.11. Pfizer, Inc.

                15.2.11.1. Company Overview

                15.2.11.2. Financial Overview

                15.2.11.3. Product Portfolio

                15.2.11.4. Business Strategies

                15.2.11.5. Recent Developments

            15.2.12. F. Hoffmann-La Roche Ltd

                15.2.12.1. Company Overview

                15.2.12.2. Financial Overview

                15.2.12.3. Product Portfolio

                15.2.12.4. Business Strategies

                15.2.12.5. Recent Developments

    List of Tables

    Table 01: Global Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 02: Global Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 03: Global Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031

    Table 04: Global Biologics Market Value (US$ Bn) Forecast, by Region, 2017–2031

    Table 05: North America Biologics Market Value (US$ Bn) Forecast, by Country, 2017–2031

    Table 06: North America Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 07: North America Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 08: North America Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031

    Table 09: Europe Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 10: Europe Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 11: Europe Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 12: Europe Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031

    Table 13: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 14: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 15: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 16: Asia Pacific Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031

    Table 17: Latin America Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 18: Latin America Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 19: Latin America Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 20: Latin America Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031

    Table 21: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Country/Sub-region, 2017–2031

    Table 22: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Product, 2017–2031

    Table 23: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Application, 2017–2031

    Table 24: Middle East & Africa Biologics Market Value (US$ Bn) Forecast, by Manufacturing, 2017–2031

    List of Figures

    Figure 01: Global Biologics Market Value (US$ Bn) Forecast, 2017–2031

    Figure 02: Global Biologics Market Value Share, by Product, 2022

    Figure 03: Global Biologics Market Value Share, by Application, 2022

    Figure 04: Global Biologics Market Value Share, by Manufacturing, 2022

    Figure 05: Global Biologics Market Value Share, by Region, 2022

    Figure 06: Global Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031

    Figure 07: Global Biologics Market Share Analysis, by Product, 2022

    Figure 08: Global Biologics Market Share Analysis, by Product, 2031

    Figure 09: Global Biologics Market Attractiveness Analysis, by Product, 2023–2031

    Figure 10: Global Biologics Market Value (US$ Bn), by Monoclonal Antibodies, 2017–2031

    Figure 11: Global Biologics Market Value Share Analysis, by Monoclonal Antibodies, 2022–2031

    Figure 12: Global Biologics Market Value (US$ Bn), by Recombinant Proteins, 2017–2031

    Figure 13: Global Biologics Market Value Share Analysis, by Recombinant Proteins, 2022–2031

    Figure 14: Global Biologics Market Value (US$ Bn), by Vaccines, 2017–2031

    Figure 15: Global Biologics Market Value Share Analysis, by Vaccines, 2022–2031

    Figure 16: Global Biologics Market Value (US$ Bn), by Cell & Gene Therapy, 2017–2031

    Figure 17: Global Biologics Market Value Share Analysis, by Cell & Gene Therapy, 2022–2031

    Figure 18: Global Biologics Market Value (US$ Bn), by Others, 2017–2031

    Figure 19: Global Biologics Market Value Share Analysis, by Others, 2022–2031

    Figure 20: Global Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031

    Figure 21: Global Biologics Market Share Analysis, by Application, 2022

    Figure 22: Global Biologics Market Share Analysis, by Application, 2031

    Figure 23: Global Biologics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 24: Global Biologics Market Value (US$ Bn), by Oncology, 2017–2031

    Figure 25: Global Biologics Market Value Share Analysis, by Oncology, 2022–2031

    Figure 26: Global Biologics Market Value (US$ Bn), by Autoimmune & Immunological Disorders, 2017–2031

    Figure 27: Global Biologics Market Value Share Analysis, by Autoimmune & Immunological Disorders, 2022–2031

    Figure 28: Global Biologics Market Value (US$ Bn), by Hematological Disorders, 2017–2031

    Figure 29: Global Biologics Market Value Share Analysis, by Hematological Disorders, 2022–2031

    Figure 30: Global Biologics Market Value (US$ Bn), by Infectious Diseases, 2017–2031

    Figure 31: Global Biologics Market Value Share Analysis, by Infectious Diseases, 2022–2031

    Figure 34: Global Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031

    Figure 35: Global Biologics Market Share Analysis, by Manufacturing, 2022

    Figure 36: Global Biologics Market Share Analysis, by Manufacturing, 2031

    Figure 37: Global Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031

    Figure 38: Global Biologics Market Value (US$ Bn), by Outsourced, 2017–2031

    Figure 39: Global Biologics Market Value Share Analysis, by Outsourced, 2022–2031

    Figure 40: Global Biologics Market Value (US$ Bn), by In-house, 2017–2031

    Figure 41: Global Biologics Market Value Share Analysis, by In-house, 2022–2031

    Figure 42: Global Biologics Market Value Share Analysis, by Region, 2022–2031

    Figure 43: Global Biologics Market Share Analysis, by Region, 2022

    Figure 44: Global Biologics Market Share Analysis, by Region, 2031

    Figure 45: Global Biologics Market Attractiveness Analysis, by Region, 2023–2031

    Figure 46: North America Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 47: North America Biologics Market Value Share Analysis, by Country, 2022–2031

    Figure 48: North America Biologics Market Attractiveness Analysis, by Country, 2023–2031

    Figure 49: North America Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031

    Figure 50: North America Biologics Market Attractiveness Analysis, by Product, 2023–2031

    Figure 51: North America Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031

    Figure 52: North America Biologics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 53: North America Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031

    Figure 54: North America Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031

    Figure 55: Europe Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 56: Europe Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 57: Europe Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 58: Europe Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031

    Figure 59: Europe Biologics Market Attractiveness Analysis, by Product, 2023–2031

    Figure 60: Europe Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031

    Figure 61: Europe Biologics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 62: Europe Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031

    Figure 63: Europe Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031

    Figure 64: Asia Pacific Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 65: Asia Pacific Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 66: Asia Pacific Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 67: Asia Pacific Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031

    Figure 68: Asia Pacific Biologics Market Attractiveness Analysis, by Product, 2023–2031

    Figure 69: Asia Pacific Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031

    Figure 70: Asia Pacific Biologics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 71: Asia Pacific Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031

    Figure 72: Asia Pacific Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031

    Figure 73: Latin America Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 74: Latin America Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 75: Latin America Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 76: Latin America Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031

    Figure 77: Latin America Biologics Market Attractiveness Analysis, by Product, 2023–2031

    Figure 78: Latin America Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031

    Figure 79: Latin America Biologics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 80: Latin America Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031

    Figure 81: Latin America Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031

    Figure 82: Middle East & Africa Biologics Market Value (US$ Bn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

    Figure 83: Middle East & Africa Biologics Market Value Share Analysis, by Country/Sub-region, 2022–2031

    Figure 84: Amgen Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2019–2022

    Figure 84: Middle East & Africa Biologics Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

    Figure 85: Amgen Inc. Breakdown of Net Sales (%), by Region/Country, 2022

    Figure 85: Middle East & Africa Biologics Market Value (US$ Bn) Share Analysis, by Product, 2022–2031

    Figure 86: Amgen Inc. R&D Expenses (US$ Bn) and Y-o-Y Growth (%), 2019–2022

    Figure 86: Middle East & Africa Biologics Market Attractiveness Analysis, by Product, 2023–2031

    Figure 87: Middle East & Africa Biologics Market Value (US$ Bn) Share Analysis, by Application, 2022–2031

    Figure 88: Middle East & Africa Biologics Market Attractiveness Analysis, by Application, 2023–2031

    Figure 89: Middle East & Africa Biologics Market Value (US$ Bn) Share Analysis, by Manufacturing, 2022–2031

    Figure 90: Middle East & Africa Biologics Market Attractiveness Analysis, by Manufacturing, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved